Pharmicell (005690) - Total Liabilities

Latest as of September 2025: ₩19.60 Billion KRW ≈ $13.28 Million USD

Based on the latest financial reports, Pharmicell (005690) has total liabilities worth ₩19.60 Billion KRW (≈ $13.28 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Pharmicell generate cash to assess how effectively this company generates cash.

Pharmicell - Total Liabilities Trend (2010–2024)

This chart illustrates how Pharmicell's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Pharmicell to evaluate the company's liquid asset resilience ratio.

Pharmicell Competitors by Total Liabilities

The table below lists competitors of Pharmicell ranked by their total liabilities.

Company	Country	Total Liabilities
Changzhou Galaxy Century Microelectronics Co Ltd SHG:688689	China	CN¥866.34 Million
Wuhan Sanzhen Industry Holding Co Ltd SHG:600168	China	CN¥18.85 Billion
Magic Software Enterprises Ltd TA:MGIC	Israel	ILA258.98 Million
Minerva S.A SA:BEEF3	Brazil	R$43.98 Billion
EuroTeleSites AG F:7YF	Germany	€1.69 Billion
Sichuan Xichang Electric Power Co Ltd SHG:600505	China	CN¥2.77 Billion
BETTER COLLECTIVE EO-01 F:9C8	Germany	€443.12 Million

Liability Composition Analysis (2010–2024)

This chart breaks down Pharmicell's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Pharmicell market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	10.82	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.18	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.15	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Pharmicell's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Pharmicell (2010–2024)

The table below shows the annual total liabilities of Pharmicell from 2010 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩12.83 Billion ≈ $8.69 Million	+5.80%
2023-12-31	₩12.12 Billion ≈ $8.21 Million	-63.25%
2022-12-31	₩32.98 Billion ≈ $22.35 Million	+8.28%
2021-12-31	₩30.46 Billion ≈ $20.64 Million	+141.01%
2020-12-31	₩12.64 Billion ≈ $8.57 Million	+7.60%
2019-12-31	₩11.75 Billion ≈ $7.96 Million	+1.03%
2018-12-31	₩11.63 Billion ≈ $7.88 Million	+49.86%
2017-12-31	₩7.76 Billion ≈ $5.26 Million	+5.44%
2016-12-31	₩7.36 Billion ≈ $4.99 Million	-56.58%
2013-12-31	₩16.95 Billion ≈ $11.49 Million	-51.36%
2012-12-31	₩34.84 Billion ≈ $23.61 Million	+90.07%
2011-12-31	₩18.33 Billion ≈ $12.42 Million	-7.59%
2010-12-31	₩19.84 Billion ≈ $13.45 Million	--

About Pharmicell

KO:005690 Korea Biotechnology

Market Cap

$736.42 Million

₩1.09 Trillion KRW

Market Cap Rank

#10574 Global

#316 in Korea

Share Price

₩18110.00

Change (1 day)

-8.40%

52-Week Range

₩10460.00 - ₩19800.00

All Time High

₩25150.00